Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 9, 2026

Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth

View original at globenewswire.com
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer Appoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief Operating Offi…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Ajay Aggarwal brings deep clinical development and operational expertise, with proven ability to advance programs from early research through late-stage development

    60% confidence

  • Josh Muntner is a highly accomplished financial leader with strong track record of executing complex financings and building trusted relationships across the investment community

    60% confidence

  • There are no guarantees that onvansertib will be utilized or prove to be commercially successful, and no guarantees that future clinical trials will be completed or successful

    60% confidence

  • Cardiff has made meaningful progress advancing onvansertib in first-line RAS-mutant metastatic colorectal cancer and remains focused on delivering clinical data to support registrational program

    60% confidence

  • Cardiff Oncology aims to overcome treatment resistance and deliver improved clinical outcomes for patients by targeting tumor vulnerabilities

    60% confidence

  • Building the right team to advance onvansertib is central to Cardiff's strategy and to ultimately delivering a potential new therapy to patients in need

    60% confidence

  • Clinical trials involve a lengthy and expensive process with uncertain outcome, and results of earlier studies may not be predictive of future trial results

    60% confidence

Cited in these Via News reports